布地奈德在国内上市了吗？

(Budesonide, Budenofalk) is a glucocorticoid with highly effective local anti-inflammatory effects. Budesonide (Budenofalk) can enhance the stability of endothelial cells, smooth muscle cells and lysosomal membranes, inhibit immune responses and reduce antibody synthesis. It is currently one of the most commonly used drugs for the treatment of asthma in countries around the world.

The recommended starting dose of budesonide for adults and children over 6 years old is 256ug per day. This dose can be sprayed once in the morning or twice in the morning and evening. That is: spray 128ug (2*64ug) into each nostril in the morning; or spray 64ug into each nostril twice in the morning and evening. No increase in effect was seen when the daily dose exceeded 256ug. After the desired clinical effect is achieved, reduce dosage to the low doses needed to control symptoms.

The safety and effectiveness of Budesonide (Budenofalk) treatment were verified in the trial: 85 patients with bronchial asthma who received treatment were selected and divided into an experimental group of 43 cases and a control group of 42 cases using the random number table method. Patients in the control group were treated with albuterol sulfate, and patients in the experimental group were treated with Budesonide (Budenofalk). After 2 weeks, the treatment effects and incidence of adverse reactions were compared. Results The treatment effectiveness rate of patients in the experimental group was 95.35%, which was significantly higher than the 69.05% in the control group, and the difference was statistically significant (P<0.05). No serious adverse reactions occurred in the two groups of patients, and the incidence of adverse reactions in the experimental group was significantly lower than that in the control group, and the difference was statistically significant (P<0.05). Conclusion Budesonide (Budenofalk) has significant efficacy and high safety when used in bronchial asthma.

Is budesonide available in China? The answer is that it has been launched in the country. (Budesonide, Budenofalk) was first developed and marketed by AstraZeneca Pharmaceutical Company in 1981. It was approved for marketing by the US FDA in August 2000. my country approved its import and marketing in November 2001. .